# Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization

> **NCT05322148** · PHASE3 · COMPLETED · sponsor: **Research Insight LLC** · enrollment: 59 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free

## Key facts

- **NCT ID:** NCT05322148
- **Lead sponsor:** Research Insight LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-03
- **Primary completion:** 2022-11-17
- **Final completion:** 2022-11-21
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05322148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05322148, "Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05322148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*